Cardiovascular complications through COVID-19?
COVID-19 can cause serious cardiovascular complications such as heart failure, heart attacks and blood clots, which can lead to strokes. The treatment of COVID-19 can interact with medications, inter -, which are used for the treatment of existing cardiovascular disease. This should be considered in the treatment of the disease.
In the current investigation, the research group of Dr. William J. Brady from the University of Virginia, it was found that COVID-may cause 19 on the one hand, serious cardiovascular complications, which strokes favor, on the other hand, the disease with medications can interact, which can be used for the treatment of existing cardiovascular diseases. The results of the study were published in the English journal “the American Journal of Emergency Medicine”.
Complications were not observed enough
The respiratory symptoms or so-called pulmonary (breathing-related) complications in COVID-19 has been already paid much attention, dooch, the cardiovascular complications that can result in death or permanent disabilities, have not been sufficiently observed, report the researchers.
Information to COVID-19 changes constantly
Therefore, the research group wanted to improve not only the understanding of the impact of COVID-19 on the body in General, but in particular, the effects on the cardiovascular System. The learning rate in this area is currently surprisingly high. The information will change weekly, if not daily, reports the research team. On the basis of an evaluation of the available scientific publications, the scientists analyzed indoor and scientists, the current state of knowledge.
24 percent of people with COVID-19 suffered from congestive heart failure
Congestive heart failure is, therefore, a special big Problem for people with COVID-19. The research team suggests that a study has already shown that almost a quarter of the people with COVID-19 (24 percent) suffered from acute heart failure, as at them the Coronavirus was first diagnosed. This does not mean, however, that 24 percent of all COVID-19 ill people will suffer from heart failure.
Congestive heart failure by COVID-19?
It is still unclear whether the heart failure was specifically caused by COVID-19, or whether the Virus has exacerbated an undiagnosed heart failure, explain the researchers. Of the persons with congestive heart failure was not, however, have been in almost the half of known that you suffer from hypertension or cardiovascular diseases.
Hazards caused by severe inflammation in the body
COVID-19 and other diseases can cause severe inflammation throughout the body. This increases the risk that in the blood vessels of accumulated fat rip-containing Plaques and heart attacks and strokes result. Influenza and certain other viruses have already been associated with an increased risk for plaque rupture within the first week after the diagnosis of the disease in this report the researchers.
Dangerous interactions of drugs
The research group also describes the possible interactions of drugs with COVID-19. For example, an antimalarial drug called hydroxychloroquine drugs interact, which regulate the heart rhythm that can cause heart damage and cardiomyopathy worsen. Remdesivir, an anti-viral medication, which is the only FDA-approved COVID-19-treatment, can lead to low blood pressure and abnormal heart rhythm, reports the researchers are more.
Interactions should be observed
The above-mentioned interactions should be taken into account when it comes to the treatment of persons with COVID-19. “With increasing experience with this new pathogen of us is aware that his night adverse effects on the respiratory system,” adds Dr. Brady. In the course of time still more information about COVID-19 and the optimal means to tackle its many presentations will be known.
Know about COVID-19 needs to be extended
“With this article we hope to broaden the Knowledge and awareness of emergency physicians about this new pathogen and its effects on the cardiovascular System,” says study author Dr. William J. Brady from the University of Virginia in a press release. (as)